Antigen News and Research

RSS

Glioma microenvironment emerges as key target for future therapies

The prognosis for glioma patients remains extremely poor despite aggressive multimodal standard therapy: maximal safe resection, radiotherapy, and temozolomide chemotherapy, with median survival rarely exceeding 15 to 18 months.

20 Aug 2026

FairJourney Bio delivers antibody engineering for novel tumor-conditional IL-12 therapeutic approach that unlocks the potential of localized cytokine activation

FairJourney Bio ("FJBio"), a global antibody discovery expert, today announced the publication of a peer-reviewed study in mAbs describing a novel approach with the potential to improve the therapeutic window of IL-12, a potent anti-tumor cytokine.

From FairJourney Biologics 20 Aug 2026

Scripps scientist receives NIAID award for immunotherapy research

Scripps Research assistant professor Tiantian Liu has received a five-year NIAID DP2 award from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH), to advance basic understanding of immune processes that could aid the design of next-generation immunotherapies.

19 Aug 2026

UC Irvine researchers develop framework to make CAR T-cell therapy safer

CAR T-cell therapy has transformed cancer care, offering new hope to patients with aggressive blood cancers who once had few treatment options.

18 Aug 2026

Engineered immune cells help eliminate severe bacterial infections effectively

Severe bacterial infections remain a major global health challenge because antibiotics alone often fail when the host immune system becomes dysfunctional.

17 Aug 2026

Ultrasound-guided SHIFTERS could expand CAR-T therapy for solid tumors

For more than a decade, CAR-T cell therapy has been one of the biggest breakthroughs in cancer medicine.

13 Aug 2026

Most veterans with low-risk prostate cancer choose active surveillance

Three decades after UC San Francisco pioneered "active surveillance" for patients with low-risk prostate cancer, a new study has found that the vast majority of veterans with the diagnosis pursued this option instead of treatment.

13 Aug 2026

Synthetic peptide enables modular detection of coronavirus protease activity

A research team has computationally designed a synthetic peptide that enables modular detection of the enzymatic activity of coronavirus 3C-like protease (3CLPro), an enzyme essential for viral replication and maturation.

13 Aug 2026

New antibody-specific AI framework accelerates discovery of therapeutic drugs

Designing an effective antibody drug is like searching for the right key in a warehouse of locks. Scientists may begin with millions-or even billions-of antibody candidates, but only a tiny fraction will recognize and bind tightly to the disease target.

13 Aug 2026

What is the optimal prostate-specific antigen cutoff to determine the success of prostate cancer treatment?

After treatment for metastatic prostate cancer, a drop in prostate-specific antigen (PSA) levels in the blood is an indicator that the treatment is working.

13 Aug 2026

Personalized T-cell therapy eliminates advanced kidney tumor in teenager

Researchers and physicians at the Hopp Children's Cancer Center Heidelberg (KiTZ) and other leading cancer centers report an exceptional treatment success in an adolescent with an advanced, therapy-resistant kidney tumor.

12 Aug 2026

Genetic tool turns soft cancer cells into immune targets

Researchers at the USC Viterbi School of Engineering and Keck School of Medicine of USC have engineered a remarkable genetic tool that addresses one of the most persistent obstacles in cancer immunotherapy: the physical softness of tumors.

11 Aug 2026

Traditional prostate cancer features fail to predict hormone therapy benefit

A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that while traditional pathological features used to classify aggressive prostate cancer -such as high-grade disease, cancer extending outside the prostate and cancer involving the seminal vesicles- after surgery can help identify patients who are more likely to have worse outcomes, they do not predict who will benefit more from adding hormone therapy to postoperative radiation.

10 Aug 2026

Optimal prostate-specific antigen cutoff linked to improved prostate cancer survival

After treatment for metastatic prostate cancer, a drop in prostate-specific antigen (PSA) levels in the blood is an indicator that the treatment is working.

10 Aug 2026

Integrated nanomaterials offer new strategies for cancer immunotherapy

Immune checkpoint inhibitors, cancer vaccines and cellular therapies have reshaped oncology, yet most patients still do not achieve lasting benefit.

9 Aug 2026

Exhausted T cells balance graft tolerance and infection risk

A comprehensive new review examines the complex role of T cell exhaustion in organ transplantation, highlighting how this dysfunctional immune state can both promote graft tolerance and create vulnerabilities to infection and malignancy.

7 Aug 2026

Early radionuclide therapy delays progression in metastatic prostate cancer

Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a phase 3 clinical trial led by Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and investigators at several other institutions worldwide.

6 Aug 2026